Rhumbline Advisers Contrafect Corp Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$3.58 - $4.9 $60,860 - $83,300	-17,000 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$4.46 - $6.68 $7,648 - $11,456	-1,715 Reduced 9.16%	17,000 $82,000
Q4 2020 Feb 10, 2021	BUY	$5.05 - $6.4 $34,850 - $44,166	6,901 Added 58.41%	18,715 $95,000
Q3 2020 Nov 12, 2020	BUY	$5.05 - $6.99 $3,610 - $4,997	715 Added 6.44%	11,814 $62,000
Q2 2020 Aug 13, 2020	BUY	$4.69 - $7.81 $52,054 - $86,683	11,099 New	11,099 $71,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.